Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum91699ArticlesСтатьиResearch ArticleDifferentsial'naya diagnostika i terapiya dementsiyДифференциальная диагностика и терапия деменцийDamulinI. VДамулинИ. В

Кафедра нервных болезней Московской медицинской академии им. И.М.Сеченова

Московская медицинская академия им. И.М.Сеченова15122003512VOL 5, NO12 (2003)ТОМ 5, №12 (2003)72172628122021Copyright ©; 2003, Consilium MedicumCopyright ©; 2003, ООО "Консилиум Медикум"2003Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/91699

Когнитивные расстройства различного генеза являются одной из наиболее важных проблем в области нейрогериатрии. Обусловлено это целым рядом причин, в том числе значительной распространенностью среди лиц пожилого и старческого возраста заболеваний, которые могут приводить к деменции. Деменция - это не нозологическая форма, а синдром, к которому могут приводить различные по этиологии патологические процессы. Правильная диагностика причины этого синдрома и адекватное лечение могут в ряде случаев привести к обратному развитию нарушений либо затормозить прогрессирование патологического процесса [1, 3, 4]. Кроме того, основанное на правильной диагностике прогнозирование течения заболевания позволяет пациенту и члену его семьи планировать свои действия.

когнитивные нарушениядеменцияболезнь Альцгеймерапожилые больныеCorey-Bloom J, Thal L.J, Galasko D et al. Diagnosis and evaluation of dementia. Neurology 1995; 45: 211-8.Golomb J, Kluger A, Ferris S.H, Garrard P. Clinician Manual on Mild Cognitive Impairment. London: Science Press, 2001; 56 p.Van Horn G. Dementia. Am J Med 1987; 83: 101-10.Zimmer R, Lauter H. Diagnosis, differential diagnosis and nosologic classification of the dementia syndrome. Pharmacopsychiatr 1988; 21: 1-7.Дамулин И.В. Болезнь Альцгеймера и сосудистая деменция/Под ред. Н.Н.Яхно. М., 2002; 85 с.Яхно Н.Н. Актуальные вопросы нейрогериатрии. В кн.: Достижения в нейрогериатрии/Под ред. Н.Н.Яхно, И.В.Дамулина. М.: ММА, 1995; 9-29.Clarfield A.M. The reversible dementias: Do they reverse? Ann Int Med 1988; 109: 476-86. 7a. Practice parameter for diagnosis and evaluation of dementia. (Summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1994; 44: 2203-6.Patterson C. The diagnosis and differential diagnosis of dementia and pseudo - dementia in the elderly. Can Fam Physician 1986; 32: 2607-10.Kellett J.M. How far to investigate dementia? Postgrad Med J 1987; 63: 963-6.Byrne E.J. Overview of differential diagnosis. Internat Psychoger 1997; 9 (suppl. 1): 39-50.Mitchell S.L. Extrapyramidal features in Alzheimer’s disease. Age Ageing 1999; 28: 401-9.Dalrymple-Alford J. Comparative neuropsychology of Lewy body and Alzheimer’s dementia. J Neurol Neurosurg Psychiatr 2001; 70: 148 p.Kosaka K, Iseki E. Diffuse Lewy body disease and diffuse neurofibrillary tangles with calcification. In: Alzheimer’s Disease: Biology, Diagnosis and Therapeutics. Editors: K.Iqbal et al. Chichester etc: John Wiley & Sons, 1997; P. 179-83.Mc Shane R.H, Nagy Z, Esiri M.M et al. Anosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology. J Neurol Neurosurg Psychiatr 2001; 70: 739-43.Ala T.A, Hughes L.F, Kyrouac G.A et al. Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease. J Neurol Neurosurg Psychiatr 2001; 70: 483-8.Calderon J, Perry R.J, Erzinclioglu S.W et al. Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease. J Neurol Neurosurg Psychiatr 2001; 70: 157-64.Doubleday E.K, Snowden J.S, Varma A.R, Neary D. Qualitative performance characteristics differentiate dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychyatr 2002; 72: 602-7.Lambon Ralph M.A, Powell J, Howard D et al. Semantic memory is impaired in both dementia with Lewy bodies and dementia of Alzheimer's type: a comparative neuropsychological study and literature review. J Neurol Neurosurg Psychiatr 2001; 70: 149-56.Mega M.S, Lee L, Dinov I.D et al. Cerebral correlates of psychotic symptoms in Alzheimer's disease. J Neurol Neurosurg Psychiatr 2000; 68: 167-71.Toone B. Cerebral dysfunction and psychotic symptoms in Alzheimer’s disease. J Neurol Neurosurg Psychiatr 2000; 69: 148-9.Walker M.P, Ayre G.A, Cummings J.L et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology 2000; 54: 1616-25.Parnetti L, Lanari A, Amici S et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer’s disease from dementia with Lewy body. Neurol Sci 2001; 22: 77-8.Kanemaru K, Yamanouchi H. Assessment of CSF homovanillic acid levels distinguishes dementia with Lewy bodies from Alzheimer’s disease. J Neurol 2002; 249: 1125-6.Watanabe H, Ieda T, Katayama T et al. Cardiac 123I-meta - iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatr 2001; 70: 781-3.Yoshita M, Taki J, Yamada M. A clinical role for [123I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's - type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatr 2001; 71: 583-8.Barber R, Ballard C, Mc Keith I.G et al. MRI volumetric study of dementia with Lewy bodies. A comparison with AD and vascular dementia. Neurology 2000; 54: 1304-9.Lobotesis K, Fenwick J.D, Phipps A et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001; 56: 643-9.Walker Z, Costa D.C, Walker R.W.H et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatr 2002; 73: 134-40.Forette F, Seux M.L, Thys L, Staessen J.A. Prevention of dementia and treatment of systolic hypertension: Syst-Eur Trial. In: Research and Practice in Alzheimer’s Disease. Vol.2. Ed. by B.Vellas, L.J.Fitten. Paris, New York: Serdi Publisher, Springer Publishing Company, 1999; P. 26-9.Launer L.J, Kalmijn S. Anti - oxidants and cognitive function: a review of clinical and epidemiologic studies. J Neural Transm 1998; 53 (suppl.): 1-8.Forette F, Rockwood K. Therapeutic intervention in dementia. In: Diagnosis and management of dementia. A manual for memory disorders team. Ed. by G.K.Wilcock et al. Oxford, New York: Oxford University Press, 1999; P. 294-310.Bullock R. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Int J Clin Pract 2002; 56 (3): 206-14.Kennedy J.S, Polinsky R.J, Johnson B et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharm 1999; 19 (6): 513-21.Anand R, Harnan R, Gharabawi G. Therapeutic effects of Exelon in the treatment of patients with Alzheimer’s disease. Neurology 1997; 48 (3, suppl. 2): A377.Doraiswamy P.M, Krishnan K.R.R, Anand R et al. Long - term effects of rivastigmine in moderately severe Alzheimer’s disease: Does early initiation of therapy offer sustained benefits? Progr Neuro-Psychopharm Biol Psychiatry 2002; 26: 705-12.Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin 2002; 18 (5): 258-64.Mc Keith I, Del Ser T, Spano P-F et al. Efficacy of rivastigmine in patients with dementia with Lewy bodies: a randomized, double blind, placebo - controlled international study. Lancet 2000; 356: 2031-6.Venneri A, Shanks M.F, Staff R.T et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s disease. NeuroReport 2002; 13: 83-7.